A double-blind, placebo-controlled trial of thymostimulin in symptomatic HIV-infected patients

G. Beall*, S. Kruger, F. Morales, D. Imagawa, J. A. Goldsmith, D. Fisher, J. Steinberg, J. Phair, S. Whaling, J. Bitran

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

6 Scopus citations


The potential therapeutic efficacy of the thymic hormone preparation, thymostimulin (TP1), in HIV infection has been studied in a multi-institutional, randomized, double-blind, placebo-controlled trial. Fifty evaluable patients with advanced AIDS-related complex (ARC) were injected with TP1 or placebo twice weekly for 6 months after 2 weeks of daily injections. The primary endpoint, progression to AIDS, was reached in nine TP1- and 11 placebo-treated subjects after 1 year. CD4 cell numbers were not affected by administration of the study drug. No toxicity was associated with TP1 treatment. We conclude that TP1 is ineffective in altering the progress of HIV disease in patients with advanced ARC.

Original languageEnglish (US)
Pages (from-to)679-681
Number of pages3
Issue number7
StatePublished - 1990


  • AIDS
  • AIDS-related complex
  • therapeutic trials
  • thymic hormones
  • thymostimulin

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Infectious Diseases


Dive into the research topics of 'A double-blind, placebo-controlled trial of thymostimulin in symptomatic HIV-infected patients'. Together they form a unique fingerprint.

Cite this